AtriCure's Competitive Positioning Under Threat from Edwards Lifesciences' New Surgical Offering

JPMorgan downgraded AtriCure to Neutral, citing rising competitive pressure from Edwards Lifesciences' planned surgical offering. This shift in analyst sentiment highlights the potential impact of competition on AtriCure's positioning in cardiac surgery devices. Despite this, other analysts maintain positive views on the company's prospects. The upcoming Q4 2025 earnings on February 17 could reset expectations around growth and profitability.